[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Indexing Sources::
Guide for Authors::
Online Submission::
Ethics::
Articles archive::
For Reviewers::
Contact us::
::
Basic and Clinical Biochemistry and Nutrition
..
DOAJ
..
CINAHL
..
EBSCO
..
IMEMR
..
ISC
..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
enamad
..
:: Volume 25, Issue 6 (Bimonthly 2021) ::
Feyz 2021, 25(6): 1314-1324 Back to browse issues page
The effect of diabetes mellitus on clinical, biochemical indications and mortality in patients with COVID-19; an analytical cross sectional study
Somaieh Karkhaneh , Alireza Abrishamib , Babak Gharaeic , Reza Vagheitabar , Mahsa Alborzi Avanaki , Fariba Samadian , Ali Zare , Leyla Karkhaneh
Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran , l_karkhaneh@yahoo.com
Abstract:   (1317 Views)
Background: Coronavirus infection in patients with pre-existing diabetes mellitus has been shown to indicate a poorer outcome compared to non-diabetic cases. This study aimed to explore disease severity and mortality in patients infected with Coronavirus 2019 disease (COVID-19) between these two groups.
Materials and Methods: The current analytical cross sectional study reviewed the medical records of 99 patients hospitalized with laboratory-confirmed COVID-19 from February 14th to February 26th, 2020. The cases were divided into non-diabetic (n=77) and diabetic (n=22) groups. The differences in clinical symptoms, biochemical parameters, length of hospital stay, CT scan analysis, and the
proportion of the patients with the outcome of mortality were compared.
Results: The statistical analysis illustrated that most of the patients were male, and compared to non-diabetic, patients with diabetes were significantly older (P=0.01). Results indicated a considerable increase in ALP, vitamin D, pO2 levels of serum and a decrease in SpO2 (P<0.05). The patients with co-existing metabolic disorders, such as cardiovascular diseases were significantly higher in the diabetic group (P<0.05). Statistics evaluation did not show significant differences between the two groups in terms of other assessed factors and CT images.
Conclusion: Based on the current study, it seems that diabetic and non-diabetic patients have almost similar clinical and paraclinical findings, so additional investigations with larger sample sizes are needed to achieve more accurate results.
Keywords: Diabetes mellitus (DM), COVID-19, Mortality
Full-Text [PDF 1026 kb]   (620 Downloads)    
Type of Study: Review | Subject: medicine, paraclinic
Received: 2021/08/1 | Revised: 2023/11/1 | Accepted: 2021/12/4 | Published: 2022/02/1
References
1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13.
2. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr 2020; 14(4): 303-10.
3. Apicella M, Campopiano M, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 2020.
4. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181(2): 271-80.e8.
5. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75(7): 1730-41.
6. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. Jama 2020; 323(18): 1775-6.
7. Drucker DJ. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications. Endocr Rev 2020; 41(3): 457-470.
8. Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348(20): 1 967-76.
9. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses وand diabetes mellitus. Am J Physiol Endocrinol Metab 2020; 318(5): E736-e41.
10. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract 2020; 162: 108142.
11. Knapp S. Diabetes and infection: is there a link?-A mini-review. Gerontology 2013; 59(2): 99-104.
12. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol 2018; 34(5): 575-84.
13. Deng SQ, Peng HJ. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. J Clin Med 2020; 9(2): 575.
14. Chen Y, Chen J, Gong X, Rong X, Ye D, Jin Y, et al. Clinical Characteristics and Outcomes of Type 2 Diabetes Patients Infected with COVID-19: A Retrospective Study. Engineering (Beijing) 2020; 6(10): 1170-7.
15. Ciardullo S, Zerbini F, Perra S, Muraca E, Cannistraci R, Lauriola M, et al. Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy. J Endocrinol Invest 2021; 44(4): 843-50.
16. Alkundi A, Mahmoud I, Musa A, Naveed S, Alshawwaf M. Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in the United Kingdom: A retrospective single centre study. Diabetes Res Clin Pract 2020; 165: 108263.
17. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care 2020; 8(1): e001343.
18. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020; e3319.
19. Gentile S, Strollo F, Ceriello A. COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used). Diabetes Res Clin Pract 2020; 162: 108137.
20. Hill MA, Mantzoros C, Sowers JR. Commentary: COVID-19 in patients with diabetes. Metabolism 2020; 107: 154217.
21. Klonoff DC, Umpierrez GE. Letter to the Editor: COVID-19 in patients with diabetes: Risk factors that increase morbidity. Metabolism 2020; 108: 154224.
22. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care 2020; 43(7): 1399-407.
23. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
24. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. Jama 2020; 323(13): 1239-42.
25. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020; 20(6): 363-74.
26. Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med 2020; 8(4): e20-e.
27. Gülsen A, Yigitbas BA, Uslu B, Drömann D, Kilinc O. The Effect of Smoking on COVID-19 Symptom Severity: Systematic Review and Meta-Analysis. Pulm Med 2020; 2020: 7590207.
28. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2. Am J Respir Crit Care Med 2020; 202(5): 756-9.
29. Moftakhar L, Moftakhar P, Piraee E, Ghaem H, Valipour A, Azarbakhsh H. Epidemiological characteristics and outcomes of COVID-19 in diabetic versus non-diabetic patients. Int J Diabetes Dev Ctries 2021;1-6.
30. Elemam NM, Hannawi H, Salmi IA, Naeem KB, Alokaily F, Hannawi S. Diabetes mellitus as a comorbidity in COVID-19 infection in the United Arab Emirates. Saudi Med J 2021; 42(2): 170-80.
31. Kreutz R, Algharably EAE-H, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res 2020; 116(10): 1688-99.
32. Soliman AT, Prabhakaran Nair A, Al Masalamani MS, De Sanctis V, Abu Khattab MA, Alsaud AE, et al. Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study. Acta Biomed 2020; 91(3): e2020010-e.
33. Li S, Wang J, Zhang B, Li X, Liu Y. Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study. Diabetes Metab J 2019; 43(3): 319-41.
34. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 Diabetes and its Impact on the Immune System. Curr Diabetes Rev 2020; 16(5): 442-9.
35. Liu Z, Li J, Huang J, Guo L, Gao R, Luo K, et al. Association Between Diabetes and COVID-19: A Retrospective Observational Study With a Large Sample of 1,880 Cases in Leishenshan Hospital, Wuhan. Front Endocrinol (Lausanne) 2020; 11: 478.
36. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010; 13(3): 170-6.
37. Duman TT, Aktas G, Atak BM, Kocak MZ, Erkus E, Savli H. Neutrophil to lymphocyte ratio as an indicative of diabetic control level in type 2 diabetes mellitus. Afr Health Sci 2019; 19(1): 1602-6.
38. Anurag A, Jha PK, Kumar A. Differential white blood cell count in the COVID-19: A cross-sectional study of 148 patients. Diabetes Metab Syndr 2020; 14(6): 2099-102.
39. Takhelmayum R, Thanpari C, Singh TP. Liver dysfunction in diabetic patients admitted in referral hospital. Bali Med J 2014; 3(3): 122-4.
40. Hanif M, Haider MA, Xi Q, Ali MJ, Ahmed MU. A Review of the Risk Factors Associated With Poor Outcomes in Patients With Coronavirus Disease 2019. Cureus 2020; 12(9): e10350.
41. Wang K, Zhang Z, Yu M, Tao Y, Xie M. 15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study. Intensive Care Med 2020; 46(7): 1472-4.
42. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
43. Singh SK, Jain R, Singh S. Vitamin D deficiency in patients with diabetes and COVID- 19 infection. Diabetes Metabolic Syndrome 2020; 14(5): 1033-5.
44. Riachy R, Vandewalle B, Moerman E, Belaich S, Lukowiak B, Gmyr V, et al. 1,25-Dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor. Apoptosis 2006; 11(2): 151-9.
45. Bhalla AK, Amento EP, Serog B, Glimcher LH. 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 1984; 133(4): 1748-54.
46. Mohan M, Cherian JJ, Sharma A. Exploring links between vitamin D deficiency and COVID-19. PLoS Pathog 2020; 16(9): e1008874.
47. Zittermann A, Pilz S, Hoffmann H, März W. Vitamin D and airway infections: a European perspective. Eur J Med Res 2016; 21: 14-.
48. Robertsen S, Grimnes G, Melbye H. Association between serum 25-hydroxyvitamin D concentration and symptoms of respiratory tract infection in a Norwegian population: the Tromsø Study. Public Health Nutr 2014; 17(4): 780-6.
49. Alipio M. Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-2019). SSRN Electronic J 2020; 3571484.
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Karkhaneh S, Abrishamib A, Gharaeic B, Vagheitabar R, Alborzi Avanaki M, Samadian F, et al . The effect of diabetes mellitus on clinical, biochemical indications and mortality in patients with COVID-19; an analytical cross sectional study. Feyz 2021; 25 (6) :1314-1324
URL: http://feyz.kaums.ac.ir/article-1-4441-en.html


Creative Commons License
This open access journal is licensed under a Creative Commons Attribution-NonCommercial ۴.۰ International License. CC BY-NC ۴. Design and publishing by Kashan University of Medical Sciences.
Copyright ۲۰۲۳© Feyz Medical Sciences Journal. All rights reserved.
Volume 25, Issue 6 (Bimonthly 2021) Back to browse issues page
مجله علوم پزشکی فیض Feyz Medical Sciences Journal
Persian site map - English site map - Created in 0.05 seconds with 46 queries by YEKTAWEB 4645